immuno oncology

China Approves Keytruda For Lung Cancer Treatment

Merck’s Keytruda is the first anti-PD-1 therapy to be approved as monotherapy, and in combination with chemotherapy, for lung cancer patients in China.

Asia’s Scientific Trailblazers: Bang Yung-Jue

On the frontlines of gastric cancer research, Professor Bang Yung-Jue is hoping to expand the arsenal of anticancer drugs and prolong patients’ lives.

China Approves Tyvyt For Hodgkin’s Lymphoma

Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody, was co-discovered by Innovent and Adimab and jointly developed by Innovent and Eli Lilly in China.

Lion TCR Raises US$20 Million In Series A Funding

The funds will be used to advance clinical trials of LioCyx™, Lion TCR’s T-cell therapy against hepatocellular carcinoma.

JW Therapeutics Raises US$90 Million In Series A Funding Round

The funds will be used to further advance JW Therapeutic's chimeric antigen receptor T-cell clinical program, develop a therapeutic pipeline and build a new commercial manufacturing facility.

Tasuku Honjo Wins 2016 Keio Medical Science Prize

Honjo was recognized for his discovery of PD-1, a negative regulator of immune responses, as well as his subsequent work in the field of immunotherapy.